North Run Capital, LP and affiliated reporting persons filed Amendment No. 2 to their Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 3,528,296 shares of TELA Bio, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: The reporting persons collectively disclosed 3,528,296 shares of TELA Bio, Inc. common stock.
  • Percent of class: The 3,528,296 shares represent approximately 7.8% of outstanding common stock as of September 30, 2026.
  • Shares outstanding basis: The percentage is calculated on 45,143,410 shares outstanding as of September 1, 2026, as reported in the issuer's proxy statement filed September 14, 2026.
  • Voting and dispositive power: All 3,528,296 shares are held with shared voting power and shared dispositive power; no reporting person holds sole voting or sole dispositive power.
  • Reporting persons: Seven reporting persons are named: North Run Capital, LP; North Run Advisors, LLC; North Run - Due North Partners, LP; North Run GP, LP; Todd B. Hammer; Thomas B. Ellis; and Michael Bosco.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.

North Run Capital Group Discloses 3,528,296 Shares in TELA Bio Amendment

According to the filing, this Schedule 13G (Amendment No. 2) was filed jointly on behalf of seven reporting persons, all of which are identified as Delaware entities or U.S. citizens. North Run Capital, LP is described as the investment manager of certain private pooled investment vehicles, including North Run - Due North Partners, LP ("Due North"), which is the vehicle through which the shares are held. Todd B. Hammer, Thomas B. Ellis, and Michael Bosco are identified as the limited partners of Due North. The filing lists a principal business address for all reporting persons of 867 Boylston St., 5th Floor #1361, Boston, MA 02116.

The filing reports that each of the seven reporting persons "may be deemed the beneficial owners of 3,528,296 shares of Common Stock as of September 30, 2026." The percent of class figure of approximately 7.8% is derived from 45,143,410 shares of common stock outstanding as of September 1, 2026, as reported in TELA Bio's proxy statement filed with the SEC on September 14, 2026. The shares carry $0.001 par value per share and are identified by CUSIP number 872381108.

All 3,528,296 shares are attributed equally to each reporting person on a shared basis for both voting and dispositive purposes. No reporting person reports sole voting power or sole dispositive power over any of the shares. The filing does not describe any specific transaction, acquisition price, or change in ownership level relative to the prior amendment.

What Was Disclosed

North Run Capital, LP and six affiliated entities and individuals filed Amendment No. 2 to their Schedule 13G, reporting shared beneficial ownership of 3,528,296 shares, or approximately 7.8%, of TELA Bio, Inc. (NASDAQ:TELA) common stock as of September 30, 2026.